Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pfizer
(NY:
PFE
)
28.16
+0.35 (+1.26%)
Official Closing Price
Updated: 7:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
32
33
Next >
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
March 08, 2023
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Lucy Scientific Discovery, Inc. Scores Major Milestone, Transitions To Revenue Generating Company With First Commercial Sale Of Psilocybin ($LSDI)
March 01, 2023
Via
AB Newswire
Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
March 01, 2023
Lucira Health Inc. (NASDAQ: LHDX) shares spiked up 264% to close at $0.52 on a massive 278 million shares traded on the announcement of FDA approval for its
Via
MarketBeat
Topics
Initial Public Offering
Exposures
COVID-19
Product Safety
Securities Market
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
February 28, 2023
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 27, 2023
From
Pfizer Inc.
Via
Business Wire
Analysts Holding As Pfizer Waits On Two Phase 3 Studies
February 24, 2023
Pfizer has two products with great potential, waiting on phase-3 study results. The resulting revenue increase should also improve share value.
Via
MarketBeat
Topics
Bankruptcy
Exposures
Financial
Legal
Dr. Harte asks: “‘Public Health?’ THE serious hazard to health?”
February 22, 2023
Corte Madera, California, United States - 02-22-2023 (PR Distribution™) -
Via
PR Distribution
Exposures
COVID-19
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
February 22, 2023
From
Pfizer Inc.
Via
Business Wire
What Are Dividend Payment Dates?
February 21, 2023
What are dividend payment dates? The payment date is the day a company pays its eligible shareholders dividends. Learn more.
Via
MarketBeat
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
February 21, 2023
From
Pfizer Inc.
Via
Business Wire
Bladder Prolapse (Cystocele) Market to Touch at High CAGR of 8.3% by 2022-2029
February 20, 2023
Bladder Prolapse (cystocele) Market is expected to grow at a CAGR of 8.3 % during the forecast period (2022-2029).
Via
SBWire
Salivary Gland Cancer Treatment Market Outlook Growth Share Overview Analysis 2022-2029
February 17, 2023
Global Salivary Gland Cancer Treatment Market to Witness Huge Growth by Key Players: Bristol-Myers Squibb Company, LGM PHARMA, Pfizer Inc., Bedford Laboratories, Baxter, sanofi-aventis U.S. LLC, Pierre...
Via
SBWire
Choroidal Neovascularization Market Share Size Trends Overview Analysis 2022-2029
February 16, 2023
Global Choroidal Neovascularization Market to Witness Huge Growth by Key Players: Bausch Health Companies Inc, Bayer AG, Gilead Sciences Inc, F.Hoffmann –La Roche AG,MaaT Pharma Novartis AG, Pfizer...
Via
SBWire
Occupational Medicines Market Is Expected to Reach at High CAGR of 5.4% by 2022-2029
February 16, 2023
Occupational medicines market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.4 % during the forecast period (2022-2029).
Via
SBWire
Zoetis, Pet-Med Specialist, Double-Digit Earnings Growth Ahead
February 16, 2023
Animal health company Zoetis is up 7.99% in the past week, after topping fourth-quarter views. Analysts see double-digit EPS growth in 2023 and 2024.
Via
MarketBeat
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
February 16, 2023
From
Pfizer Inc.
Via
Business Wire
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
February 16, 2023
From
Pfizer Inc.
Via
Business Wire
Ziprasidone Market Trends Share Demand Overview Analysis 2022-2029
February 14, 2023
Global Ziprasidone Market to Witness Huge Growth by Key Players: Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals, Apotex, Dr. Reddy's laboratories Ltd., Wockhardt, Aurobindo...
Via
SBWire
Spinal Stenosis Treatment Market to Grow with a Growth Rate of 4% During 2022 to 2029
February 14, 2023
Spinal Stenosis Treatment Market size was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 4% during the forecast period (2022-2029).
Via
SBWire
Undifferentiated Pleomorphic Sarcoma Therapeutics Market Share Volume Demand 2022 to 2029
February 14, 2023
The Undifferentiated Pleomorphic Sarcoma Therapeutics Market size was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a high CAGR during the forecast period...
Via
SBWire
Water for Injection Market Trends Outlook Demand 2023 -2030
February 13, 2023
Global Water for Injection Market to Witness Huge Growth by Key Players: Abbott Laboratories, AdvaCare Pharma, B. Braun SE, FUJIFILM Holdings Corp., GlaxoSmithKline Plc, Merit Healthcare International...
Via
SBWire
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
February 10, 2023
From
Pfizer Inc.
Via
Business Wire
Gemcitabine HCL Market to Grow with a Growth Rate of 7% During 2023 to 2030
February 10, 2023
Gemcitabine HCL Market size is expected to reach at a CAGR of 7% during the forecast period (2023-2030).
Via
SBWire
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
February 10, 2023
By Julian Richard, Benzinga
Via
TheNewswire.com
Topics
Intellectual Property
Exposures
Intellectual Property
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
February 09, 2023
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030)
Via
SBWire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 09, 2023
From
Pfizer Inc.
Via
Business Wire
Musculoskeletal Diseases Treatment Market Is Poised to Cross at High CAGR of 4.9% in 2023-2030
February 08, 2023
The Musculoskeletal Diseases Treatment Market size was valued at US$ YY million in 2023 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 4.8% during the forecast period...
Via
SBWire
Pain Relief Medication Market to Witness Huge Growth by Key Players: Pfizer Inc., Johnson & Johnson Services Inc., Bayer AG, Sanofi S.A., GlaxoSmithKline Plc.
February 08, 2023
Global Pain Relief Medication Market By Material (Acute, Chronic), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
Via
SBWire
Active Pharmaceutical Ingredients Market May Set Epic Growth Story : Pfizer, Novartis, Sanofi
February 07, 2023
Stay up-to-date with Active Pharmaceutical Ingredients Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.
Via
SBWire
Topics
Death
Exposures
Death
Biosimilars Market 2023 Industry Size, Share, Growth and Analysis by Demand, Opportunity, Key Players, Regional Development and Forecast 2029
February 03, 2023
Biosimilars Market Size, Share and Forecast 2023-2029 Key Players are – Samsung Biologics, Intas Pharmaceuticals Ltd, Celltrion, Reliance Life Sciences, Pfizer, Coherus BioSciences, Amgen, Biocon Ltd
Via
SBWire
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.